Healthcare Technology Report January 29, 2025
Verdiva Bio, a developer of obesity therapies, has launched as a clinical-stage biopharmaceutical company focused on creating innovative therapies for obesity and other cardiometabolic disorders. The company raised $411 million in an oversubscribed Series A financing round, co-led by Forbion and General Atlantic, with additional backing from RA Capital Management, OrbiMed, and others. Verdiva plans to advance a portfolio of next-generation treatments, including first-in-class and best-in-class oral and injectable options. CEO Khurem Farooq emphasized the company’s goal to offer better treatment options for individuals with obesity and related...
Today's Sponsors
Today's Sponsor